Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Unichem Labs net loss...

    Unichem Labs net loss narrows to Rs 22 crore in September quarter

    Farhat NasimWritten by Farhat Nasim Published On 2019-11-05T09:15:01+05:30  |  Updated On 5 Nov 2019 9:15 AM IST
    Unichem Labs net loss narrows to Rs 22 crore in September quarter

    Unichem Labs had posted a net loss of Rs 41.03 crore for the corresponding period of the previous fiscal, the company said in a filing to the BSE.


    New Delhi: Drug firm Unichem Laboratories on Saturday reported a narrowing of its consolidated net loss to Rs 22.20 crore for the quarter ended September 30, 2019.


    The company had posted a net loss of Rs 41.03 crore for the corresponding period of the previous fiscal, Unichem Laboratories said in a filing to the BSE.


    Also Read: Unichem Labs standalone net profit declines 99.83 per cent in Q3


    Its consolidated revenue from operations stood at Rs 295.60 crore for the quarter under consideration. It was Rs 261.15 crore for the same period a year ago, it added.


    Unichem Labs manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. The Company has skills in product development, process chemistry and manufacturing complex API as well as dosage forms.


    Also Read: Unichem Laboratories Q4 net profit up 13% at Rs 31.46 cr

    pharm anewspharmapharma news indiauncihem revenueunichem financial resultsUnichem LaboratoriesUnichem Labsunichem lossunichem q2
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok